Is the stock a buy, sell, or hold at $27?<\/p>\n
![\"Scientists](\"https:\/\/www.newsbeep.com\/us\/wp-content\/uploads\/2026\/04\/a5c71f5b16cf9aeacd9abcdd3f0be2d9.jpeg\")
Image source: Getty Images. Can Pfizer get back to growing its business? <\/p>\n
Ultimately, whether or not Pfizer’s stock can go on a prolonged rally will depend on the outlook growth investors<\/a> have for the business. At a time when the healthcare sector is under pressure to reduce costs, and there’s growing skepticism about vaccines, it’s not all that surprising that investors aren’t feeling all that excited about many healthcare stocks. Pfizer, which generates a lot of revenue from vaccines and which got a big boost from its COVID vaccine and pill in recent years, is certainly no exception.<\/p>\n Its struggles can be summed up with the chart below, which highlights just how impressive its growth rate was during the pandemic, and how quickly it came crashing back down.<\/p>\n Pfizer has been involved in many acquisitions in recent years in an effort to grow its business, but it’s proving to be a challenging road ahead. A few years ago, CEO Albert Bourla outlined a growth strategy that leaned heavily on acquisitions and in-house development, through which Pfizer could add $25 billion to its top line by the end of the decade, more than offsetting a possible $18 billion decline in revenue due to growing competition from generics. Investors, however, don’t appear to be convinced that it’s on the right path.<\/p>\n Why Pfizer’s stock might be worth the risk <\/p>\n Pfizer is navigating a challenging path ahead, but I believe its efforts will pay off. This is the healthcare sector after all, and it can sometimes take just one big drug approval that makes a stock a hot buy again. Pfizer isn’t at that stage yet, but with over 100 drug candidates in its pipeline, odds are, it’ll have more than a few approvals coming its way in the near future.<\/p>\n Plus, the stock’s valuation is extremely low<\/a>, offering investors a solid margin of safety. It trades at just nine times its expected future earnings (based on analyst estimates). That’s a dirt cheap valuation for a company that generated $63 billion in revenue last year, and which could be on the cusp of much more growth. Investing in Pfizer comes with a bit of risk, but the stock also possesses a lot of potential upside in the long run.<\/p>\n Should you buy stock in Pfizer right now? <\/p>\n Before you buy stock in Pfizer, consider this:<\/p>\n The Motley Fool Stock Advisor analyst team just identified what they believe are the\u00a010 best stocks<\/a> for investors to buy now\u2026 and Pfizer wasn\u2019t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.<\/p>\n Consider when Netflix made this list on December 17, 2004… if you invested $1,000 at the time of our recommendation,\u00a0you\u2019d have $492,752!* Or when Nvidia made this list on April 15, 2005… if you invested $1,000 at the time of our recommendation, you\u2019d have $1,327,935!*<\/p>\n Now, it\u2019s worth noting\u00a0Stock Advisor\u2019s total average return is 991% \u2014 a market-crushing outperformance compared to 201% for the S&P 500.\u00a0Don’t miss the latest top 10 list, available with\u00a0Stock Advisor, and join an investing community built by individual investors for individual investors.<\/p>\n See the 10 stocks \u00bb<\/a><\/p>\n *Stock Advisor returns as of April 28, 2026. <\/p>\n David Jagielski, CPA<\/a> has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Pfizer. The Motley Fool has a disclosure policy<\/a>.<\/p>\n<\/a> PFE Revenue (Quarterly YoY Growth)<\/a> data by YCharts<\/a> <\/p>\n